Artivion, Inc. · NYSE:AORT
Artivion — CryoLife — Merger or Acquisition (March 2011)
8 slides from Artivion's merger presentation, Mar 29, 2011
Slide 1: CryoLife Signs Definitive Agreement to Acquire Cardiogenesis Corporation
EXHIBIT 99.2 SLIDE PRESENTATION Slide One [picture of binoculars, boy and medical equipment] CryoLife® - Life Restoring Technologies® CryoLife Signs Definitive Agreement to Acquire Cardiogenesis Corporation [picture of doctor with syringe, two girls and a doctor] Slide Two [picture of CryoLife headq
Slide 2: Growth Strategy and Addressable Market
[graph showing $8.7 million in 2006, $17.5 million in 2007, $22.8 million in 2008, $35.1 million in 2009 and $40.8 million in 2010] Slide Nine Growth Strategy • Increase addressable market opportunity • Expand product offerings to cardiac and vascular surgeons through internal pipeline and strategic
Slide 3: Worldwide Sales and Distribution; Cardiogenesis Transaction Summary
Slide Fifteen Worldwide Sales and Distribution United States • Approximately 50 person direct sales force and managers targeting cardiac and vascular surgeons exclusively (approximately 65 after Cardiogenesis transaction) • Relationships with over 1,000 cardiac and vascular surgeons • Access to worl
Slide 4: Regulatory and Clinical Status; FDA Approved Products
• Addition of adjunctive biologics increases market potential to >$700 million Slide Twenty One Regulatory and Clinical Status • FDA approved • TMR is Medicare/Medicaid reimbursed • CE Mark with limited international selling efforts • TMR supported by five year clinical data • TMR endorsed by major
Slide 5: Patient Benefits; Cardiogenesis Summary; Financial Guidance
Patient Benefits • Reduce Symptoms (Angina) • Improve Clinical Outcome – Exercise Tolerance Testing (ETT) – Quality of Life (QoL) – Late Cardiac Events • Physiologic Improvement* – Myocardial Perfusion – Left Ventricular Ejection Fraction (LVEF) * Potential benefits with adjunctive stem cell therapy
Slide 6: Forward-looking statements and risk factors
making it more difficult to maintain relationships with employees, customers, business partners or governmental entities. Furthermore, CryoLife’s ability to fully realize the anticipated benefits of the transaction with Cardiogenesis may be materially adversely impacted if the integration of Cardiog
Slide 7: Forward-looking statements and risk factors (continued)
clinical trials or otherwise adversely affect CryoLife’s Cardiogenesis business, if Cardiogenesis’ independent contract manufacturers fail to timely deliver sufficient quantities of some of CryoLife’s Cardiogenesis products and components in a timely manner, CryoLife’s Cardiogenesis operations may b
Slide 8: Slide 8